BioLineRx Ltd (BLRX)

Currency in USD
4.510
-0.050(-1.10%)
Closed·
After Hours
4.420-0.090(-2.00%)
·
BLRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BLRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.4344.580
52 wk Range
2.30035.600
Key Statistics
Prev. Close
4.56
Open
4.56
Day's Range
4.434-4.58
52 wk Range
2.3-35.6
Volume
26.02K
Average Volume (3m)
690.71K
1-Year Change
-86.26%
Book Value / Share
0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
26.000
Upside
+476.50%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

BioLineRx Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

BioLineRx Ltd Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd Earnings Call Summary for Q3/2024

  • BioLineRx reports Q3 revenue of $4.9M, net loss of $5.8M, and strong cash position of $29.2M
  • Major licensing deal with Airmid Limited for Motixafortide; strategic shift to focus on clinical development in Israel
  • U.S. commercial operations closed; company expects over 70% reduction in expenses for 2025
  • Pancreatic cancer program advancing; interim data expected in 2026
  • Plans to introduce 1-2 new clinical assets in next two years; revenues from China partnership expected in 2025
Last Updated: 25/11/2024, 16:06
Read Full Transcript

Compare BLRX to Peers and Sector

Metrics to compare
BLRX
Peers
Sector
Relationship
P/E Ratio
−5.6x−2.1x−0.5x
PEG Ratio
−0.06−0.030.00
Price/Book
0.9x2.7x2.6x
Price / LTM Sales
0.9x9.3x3.2x
Upside (Analyst Target)
-423.6%40.5%
Fair Value Upside
Unlock4.1%4.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 26.000
(+476.50% Upside)

Earnings

Latest Release
May 27, 2025
EPS / Forecast
-- / -0.10
Revenue / Forecast
255.00K / 3.96M
EPS Revisions
Last 90 days

BLRX Income Statement

People Also Watch

23.320
SBET
-9.65%
2.24
BMGL
-2.18%
41.75
BMNR
+5.70%
1.27
KLTO
0.00%
16.9500
QUBT
-2.98%

FAQ

What Stock Exchange Does BioLineRx Trade On?

BioLineRx is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for BioLineRx?

The stock symbol for BioLineRx is "BLRX."

What Is the BioLineRx Market Cap?

As of today, BioLineRx market cap is 19.08M.

What Is BioLineRx's Earnings Per Share (TTM)?

The BioLineRx EPS (TTM) is -0.00.

From a Technical Analysis Perspective, Is BLRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has BioLineRx Stock Split?

BioLineRx has split 2 times.

How Many Employees Does BioLineRx Have?

BioLineRx has 28 employees.

What is the current trading status of BioLineRx (BLRX)?

As of 25 Jul 2025, BioLineRx (BLRX) is trading at a price of 4.51, with a previous close of 4.56. The stock has fluctuated within a day range of 4.43 to 4.58, while its 52-week range spans from 2.30 to 35.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.